September 8, 2016 / 11:27 AM / a year ago

BRIEF-Immunovaccine announces dosing of first patient in Phase 1B clinical trial for DPX-Survivac

Sept 8 (Reuters) - Immunovaccine Inc

* Survivac in combination with Incyte’s IDO1 enzyme inhibitor Epacadostat Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below